Do analysts recommend ADTX or SCPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scopus BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, ADTX or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Aditxt. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.39 -$41.71M -$100.79 thousand N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Do analysts prefer ADTX or SYRS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, ADTX or SYRS?

Aditxt has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.39 -$41.71M -$100.79 thousand N/A Syros Pharmaceuticals $386K 0.03 -$164.57M -$3.03 N/A

Do analysts recommend NAVB or ADTX?

Given Navidea Biopharmaceuticals' higher probable upside, research analysts clearly believe Navidea Biopharmaceuticals is more favorable than Aditxt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Navidea Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend PXMD or ADTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PaxMedica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, PXMD or ADTX?

PaxMedica has higher earnings, but lower revenue than Aditxt. PaxMedica is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Aditxt $14.34K 0.39 -$41.71M -$100.79 thousand N/A

Is PXMD or ADTX more profitable?

PaxMedica has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Aditxt -360,152.50% -374.60% -105.93%

Do analysts recommend ADTX or GNCA?

Given Genocea Biosciences' higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than Aditxt. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genocea Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, ADTX or GNCA?

Genocea Biosciences has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.39 -$41.71M -$100.79 thousand N/A Genocea Biosciences $1.91M 0.00 -$33.20M -$0.61 N/A

Is ADTX or GNCA more profitable?

Genocea Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Genocea Biosciences' return on equity of -182.88% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Genocea Biosciences N/A -182.88% -62.76%

Aditxt (ADTX) Competitors

$0.0068 0.00 (-5.56%)

As of 09/3/2026 03:59 PM Eastern

Compare

ADTX vs. SCPS, SYRS, NAVB, PXMD, and GNCA

Should you buy Aditxt stock or one of its competitors? Aditxt's main competitors and comparable companies include Scopus BioPharma (SCPS), Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), PaxMedica (PXMD), and Genocea Biosciences (GNCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aditxt compare to Scopus BioPharma?

Aditxt (NASDAQ:ADTX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Scopus BioPharma has lower revenue, but higher earnings than Aditxt.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Scopus BioPharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Scopus BioPharma's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Scopus BioPharma	N/A	N/A	N/A

Aditxt has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market.

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Scopus BioPharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Aditxt shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Scopus BioPharma beats Aditxt on 5 of the 9 factors compared between the two stocks.

How does Aditxt compare to Syros Pharmaceuticals?

Aditxt (NASDAQ:ADTX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Aditxt. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Aditxt. Aditxt's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Syros Pharmaceuticals	Neutral

Aditxt has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

Aditxt has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Syros Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Syros Pharmaceuticals beats Aditxt on 8 of the 13 factors compared between the two stocks.

How does Aditxt compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Given Navidea Biopharmaceuticals' higher probable upside, research analysts clearly believe Navidea Biopharmaceuticals is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Navidea Biopharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Navidea Biopharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Aditxt	-360,152.50%	-374.60%	-105.93%

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Aditxt has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Aditxt	Neutral

Summary

Navidea Biopharmaceuticals beats Aditxt on 8 of the 12 factors compared between the two stocks.

How does Aditxt compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

PaxMedica has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Aditxt	-360,152.50%	-374.60%	-105.93%

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the broader market. Comparatively, Aditxt has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Aditxt	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PaxMedica	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PaxMedica has higher earnings, but lower revenue than Aditxt. PaxMedica is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A

Summary

Aditxt beats PaxMedica on 7 of the 11 factors compared between the two stocks.

How does Aditxt compare to Genocea Biosciences?

Aditxt (NASDAQ:ADTX) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

15.5% of Aditxt shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genocea Biosciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Genocea Biosciences' return on equity of -182.88% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Genocea Biosciences	N/A	-182.88%	-62.76%

Aditxt has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Given Genocea Biosciences' higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than Aditxt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genocea Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Genocea Biosciences has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Genocea Biosciences	Neutral

Summary

Genocea Biosciences beats Aditxt on 9 of the 12 factors compared between the two stocks.

Get Aditxt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADTX vs. The Competition

Export

Metric	Aditxt	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.29	25.25
Price / Sales	0.39	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.00	12.33	12.92	6.14
Net Income	-$41.71M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.60%	0.60%	-0.27%
1 Month Performance	N/A	6.96%	5.72%	0.68%
1 Year Performance	N/A	9.45%	25.33%	14.84%

Aditxt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADTX Aditxt	0.174 of 5 stars	$0.01 -5.6%	N/A	-100.0%	$6K	$14.34K	N/A	60	Gap Down
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$17K	N/A	N/A	9
SYRS Syros Pharmaceuticals	N/A	$0.00 +300.0%	N/A	-63.6%	$11K	$386K	N/A	120	Gap Up
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$8K	N/A	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADTX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aditxt (ADTX) Competitors

ADTX vs. SCPS, SYRS, NAVB, PXMD, and GNCA

How does Aditxt compare to Scopus BioPharma?

Summary

How does Aditxt compare to Syros Pharmaceuticals?

Summary

How does Aditxt compare to Navidea Biopharmaceuticals?

Summary

How does Aditxt compare to PaxMedica?

Summary

How does Aditxt compare to Genocea Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aditxt (ADTX) Competitors

ADTX vs. SCPS, SYRS, NAVB, PXMD, and GNCA

How does Aditxt compare to Scopus BioPharma?

Which has better valuation & earnings, ADTX or SCPS?

Is ADTX or SCPS more profitable?

Which has more volatility & risk, ADTX or SCPS?

Does the media prefer ADTX or SCPS?

Do analysts recommend ADTX or SCPS?

Do insiders & institutionals hold more shares of ADTX or SCPS?

Summary

How does Aditxt compare to Syros Pharmaceuticals?

Does the media prefer ADTX or SYRS?

Which has more volatility and risk, ADTX or SYRS?

Which has preferable earnings and valuation, ADTX or SYRS?

Do analysts prefer ADTX or SYRS?

Is ADTX or SYRS more profitable?

Do insiders and institutionals hold more shares of ADTX or SYRS?

Summary

How does Aditxt compare to Navidea Biopharmaceuticals?

Do analysts recommend NAVB or ADTX?

Is NAVB or ADTX more profitable?

Which has higher valuation and earnings, NAVB or ADTX?

Do institutionals and insiders hold more shares of NAVB or ADTX?

Which has more risk & volatility, NAVB or ADTX?

Does the media favor NAVB or ADTX?

Summary

How does Aditxt compare to PaxMedica?

Is PXMD or ADTX more profitable?

Which has more risk and volatility, PXMD or ADTX?

Do insiders & institutionals believe in PXMD or ADTX?

Does the media prefer PXMD or ADTX?

Do analysts recommend PXMD or ADTX?

Which has higher earnings and valuation, PXMD or ADTX?

Summary

How does Aditxt compare to Genocea Biosciences?

Do institutionals and insiders have more ownership in ADTX or GNCA?

Is ADTX or GNCA more profitable?

Which has more volatility and risk, ADTX or GNCA?

Do analysts recommend ADTX or GNCA?

Which has better earnings & valuation, ADTX or GNCA?

Does the media refer more to ADTX or GNCA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools